Preview

Вопросы современной педиатрии

Расширенный поиск

Семейная средиземноморская лихорадка: современные подходы к диагностике и лечению

https://doi.org/10.15690/vsp.v17i5.1953

Полный текст:

Аннотация

Семейная средиземноморская  лихорадка  — типичное моногенное  заболевание  с аутосомно-рецессивным типом наследования;  обусловлено  мутациями в гене MEFV, кодирующем белок пирин. Является сравнительно редкой патологией  в практике  педиатров  и ревматологов  Российской  Федерации.  В статье  приводятся  современные данные о распространенности  заболевания,  представлена  полная на сегодняшний день клиническая картина аутовоспалительного синдрома, рассматриваются диагностические критерии и методы лечения пациентов с семейной средиземноморской лихорадкой.

Об авторах

М. М. Костик
Санкт-Петербургский государственный педиатрический медицинский университет
Россия

Костик Михаил Михайлович - доктор медицинских наук, доцент, и.о. заведующего кафедрой госпитальной педиатрии СПбГПМУ.

194100, Санкт-Петербург, ул. Литовская, д. 2; тел.: +7 (812) 416-52-98



О. В. Жогова
Крымский федеральный университет им. В.И. Вернадского; Республиканская детская клиническая больница
Россия
Симферополь.


Н. В. Лагунова
Крымский федеральный университет им. В.И. Вернадского
Россия
Симферополь.


С. В. Ивановский
Крымский федеральный университет им. В.И. Вернадского; Республиканская детская клиническая больница
Россия
Симферополь.


О. Л. Колобова
Санкт-Петербургский государственный педиатрический медицинский университет
Россия

194100, Санкт-Петербург, ул. Литовская, д. 2; тел.: +7 (812) 416-52-98



Л. Н. Мельникова
Санкт-Петербургский государственный педиатрический медицинский университет
Россия

194100, Санкт-Петербург, ул. Литовская, д. 2; тел.: +7 (812) 416-52-98



Список литературы

1. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97(1):133–144. doi: 10.1016/s0092-8674(00)80721-7.

2. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90(4):797–807. doi: 10.1016/s0092-8674(00)80539-5.

3. French FMFC. A candidate gene for familial Mediterranean fever. Nat Genet. 1997;17(1):25–31. doi: 10.1038/ng0997-25.

4. igh.cnrs.fr [Internet]. Institut de genetique humaine. Infevers: an online database for autoinflammatory mutations [cited 2018 Aug 14]. Available from: http://fmf.igh.cnrs.fr/ISSAID/infevers/.

5. Park H, Bourla AB, Kastner DL, et al. Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol. 2012;12(8):570–580. doi: 10.1038/nri3261.

6. Simon A, van der Meer JW. Pathogenesis of familial periodic fever syndromes or hereditary autoinflammatory syndromes. Am J Physiol Regul Integr Comp Physiol. 2007;292(1):R86–98. doi: 10.1152/ajpregu.00504.2006.

7. Chae JJ, Wood G, Masters SL, et al. The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci U S A. 2006;103(26):9982–9987. doi: 10.1073/pnas.0602081103.

8. Aksentijevich I, Kastner DL. Genetics of monogenic autoinflammatory diseases: past successes, future challenges. Nat Rev Rheumatol. 2011;7(8):469–478. doi: 10.1038/nrrheum.2011.94.

9. Sohar E, Gafni J, Pras M, Heller H. Familial Mediterranean fever. A survey of 470 cases and review of the literature. Am J Med. 1967;43(2):227–253. doi: 10.1016/0002-9343(67)90167-2.

10. Kastner DL, Aksentijevich I. Intermittent and periodic arthritis syndromes. In: Koopman WJ, Moreland LW, editors. Arthritis and allied conditions: a textbook of rheumatology. 15th ed. Philadelphia, USA: Lippincott Williams and Wilkins; 2005. pp. 1411–1461.

11. Салугина С.О., Кузьмина Н.Н., Федоров Е.С. Аутовоспалительные синдромы — «новая» мультидисциплинарная проблема педиатрии и ревматологии // Педиатрия. Журнал им. Г.Н. Сперанского. — 2012. — Т. 91. — № 5 — С. 120–132.

12. Yilmaz E, Ozen S, Balci B, et al. Mutation frequency of Familial Mediterranean Fever and evidence for a high carrier rate in the Turkish population. Eur J Hum Genet. 2001;9(7):553–555. doi: 10.1038/sj.ejhg.5200674.

13. Touitou I. Standardized testing for mutations in familial Mediterranean fever. Clin Chem. 2003;49(11):1781–1782. doi: 10.1373/clinchem.2003.025791.

14. Jarjour RA, Al-Berrawi S. Familial Mediterranean fever in Syrian children: phenotype-genotype correlation. Rheumatol Int. 2015;35(4):629–634. doi: 10.1007/s00296-014-3116-x.

15. Touitou I. The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet. 2001;9(7):473–483. doi: 10.1038/sj.ejhg.5200658.

16. Yigit S, Bagci H, Ozkaya O, et al. MEFV mutations in patients with familial Mediterranean fever in the Black Sea region of Turkey: Samsun experience [corrected]. J Rheumatol. 2008;35(1):106–113.

17. Yalcinkaya F, Ozen S, Ozcakar ZB, et al. A new set of criteria for the diagnosis of familial Mediterranean fever in childhood. Rheumatology (Oxford). 2009;48(4):395–398. doi: 10.1093/rheumatology/ken509.

18. Barut K, Sahin S, Adrovic A, et al. Familial Mediterranean fever in childhood: a single-center experience. Rheumatol Int. 2018;38(1):67–74. doi: 10.1007/s00296-017-3796-0.

19. Ece A, Cakmak E, Uluca U, et al. The MEFV mutations and their clinical correlations in children with familial Mediterranean fever in southeast Turkey. Rheumatol Int. 2014;34(2):207–212. doi: 10.1007/s00296-013-2858-1.

20. Yalcinkaya F, Cakar N, Misirlioglu M, et al. Genotype-phenotype correlation in a large group of Turkish patients with familial mediterranean fever: evidence for mutation-independent amyloidosis. Rheumatology (Oxford). 2000;39(1):67–72. doi: 10.1093/rheumatology/39.1.67.

21. Samuels J, Aksentijevich I, Torosyan Y, et al. Familial Mediterranean fever at the millennium. Clinical spectrum, ancient mutations, and a survey of 100 American referrals to the National Institutes of Health. Medicine (Baltimore). 1998;77(4):268–297. doi: 10.1097/00005792-199807000-00005.

22. Ben-Chetrit E, Touitou I. Familial mediterranean Fever in the world. Arthritis Rheum. 2009;61(10):1447–1453. doi: 10.1002/art.24458.

23. Zadeh N, Getzug T, Grody WW. Diagnosis and management of familial Mediterranean fever: integrating medical genetics in a dedicated interdisciplinary clinic. Genet Med. 2011;13(3):263–269. doi: 10.1097/GIM.0b013e31820e27b1.

24. Kone-Paut I, Hentgen V, Touitou I. Current data on familial Mediterranean fever. Joint Bone Spine. 2011;78(2):111–114. doi: 10.1016/j.jbspin.2010.09.021.

25. Gul A, Ozdogan H, Erer B, et al. Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever. Arthritis Res Ther. 2015;17:243. doi: 10.1186/s13075-015-0765-4.

26. Berkun Y, Ben-Chetrit E, Klar A, Ben-Chetrit E. Peritoneal adhesions and intestinal obstructions in patients with familial Mediterranean fever are they more frequent? Semin Arthritis Rheum. 2007;36(5):316–321. doi: 10.1016/j.semarthrit.2006.11.002.

27. Kasifoglu T, Cansu DU, Korkmaz C. Frequency of abdominal surgery in patients with familial Mediterranean fever. Intern Med. 2009;48(7):523–526. doi: 10.2169/internalmedicine.48.1602.

28. Rawashdeh MO, Majeed HA. Familial Mediterranean fever in Arab children: the high prevalence and gene frequency. Eur J Pediatr. 1996;155(7):540–544. doi: 10.1007/bf01957901.

29. Tunca M, Akar S, Onen F, et al. Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore). 2005;84(1):1–11. doi: 10.1097/01.md.0000152370.84628.0c.

30. Brik R, Shinawi M, Kasinetz L, Gershoni-Baruch R. The musculoskeletal manifestations of familial Mediterranean fever in children genetically diagnosed with the disease. Arthritis Rheum. 2001;44(6):1416–1419. doi: 10.1002/1529-0131(200106)44:6<1416::aid-art236>3.0.co;2-6.

31. Ozen S, Bakkaloglu A, Yilmaz E, et al. Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? J Rheumatol. 2003;30(9):2014–2018.

32. Borman P, Gokoglu F, Tasbas O, et al. Familial Mediterranean fever-related spondyloarthropathy. Singapore Med J. 2009;50(3): e116–119.

33. Eshed I, Rosman Y, Livneh A, et al. Exertional leg pain in familial Mediterranean fever: a manifestation of an underlying enthesopathy and a marker of more severe disease. Arthritis Rheumatol. 2014;66(11):3221–3226. doi: 10.1002/art.38797.

34. Langevitz P, Livneh A, Zemer D, et al. Seronegative spondyloarthropathy in familial Mediterranean fever. Semin Arthritis Rheum. 1997;27(2):67–72. doi: 10.1016/s0049-0172(97)80007-8.

35. Padeh S, Shinar Y, Pras E, et al. Clinical and diagnostic value of genetic testing in 216 Israeli children with Familial Mediterranean fever. J Rheumatol. 2003;30(1):185–190.

36. Korkmaz C, Ozdogan H, Kasapcopur O, Yazici H. Acute phase response in familial Mediterranean fever. Ann Rheum Dis. 2002;61(1):79–81. doi: 10.1136/ard.61.1.79.

37. Bayram MT, Cankaya T, Bora E, et al. Risk factors for subclinical inflammation in children with Familial Mediterranean fever. Rheumatol Int. 2015;35(8):1393–1398. doi: 10.1007/s00296-015-3227-z.

38. Kilic A, Varkal MA, Durmus MS, et al. Relationship between clinical findings and genetic mutations in patients with familial Mediterranean fever. Pediatr Rheumatol Online J. 2015;13:59. doi: 10.1186/s12969-015-0057-1.

39. Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007;356(23):2361–2371. doi: 10.1056/NEJMoa070265.

40. Hentgen V, Grateau G, Kone-Paut I, et al. Evidence-based recommendations for the practical management of Familial Mediterranean Fever. Semin Arthritis Rheum. 2013;43(3):387–391. doi: 10.1016/j.semarthrit.2013.04.011.

41. Giancane G, Ter Haar NM, Wulffraat N, et al. Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. Ann Rheum Dis. 2015;74(4):635–641. doi: 10.1136/annrheumdis-2014-206844.

42. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum. 1997;40(10): 1879–1885. doi: 10.1002/art.1780401023.

43. Pras M. Familial Mediterranean fever: from the clinical syndrome to the cloning of the pyrin gene. Scand J Rheumatol. 1998;27(2): 92–97. doi: 10.1080/030097498440949.

44. Ozcakar ZB, Yalcinkaya F, Cakar N, et al. Application of the new pediatric criteria and Tel Hashomer criteria in heterozygous patients with clinical features of FMF. Eur J Pediatr. 2011;170(8): 1055–1057. doi: 10.1007/s00431-011-1404-y.

45. Kondi A, Hentgen V, Piram M, et al. Validation of the new paediatric criteria for the diagnosis of familial Mediterranean fever: data from a mixed population of 100 children from the French reference centre for auto-inflammatory disorders. Rheumatology (Oxford). 2010;49(11):2200–2203. doi: 10.1093/rheumatology/keq252.

46. Berkun Y, Eisenstein EM. Diagnostic criteria of familial Mediterranean fever. Autoimmun Rev. 2014;13(4–5):388–390. doi: 10.1016/j.autrev.2014.01.045.

47. Ben-Zvi I, Livneh A. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy. Nat Rev Rheumatol. 2011;7(2): 105–112. doi: 10.1038/nrrheum.2010.181.

48. Celkan T, Celik M, Kasapcopur O, et al. The anemia of familial Mediterranean fever disease. Pediatr Hematol Onco. 2005;22(8): 657–665. doi: 10.1080/08880010500278681.

49. Aharoni D, Hiller N, Hadas-Halpern I. Familial Mediterranean fever: abdominal imaging findings in 139 patients and review of the literature. Abdom Imaging. 2000;25(3):297–300. doi: 10.1007/s002610000006.

50. Livneh A, Langevitz P, Zemer D, et al. The changing face of familial Mediterranean fever. Semin Arthritis Rheum. 1996;26(3):612–627. doi: 10.1016/S0049-0172(96)80012-6.

51. Salah S, El-Masry SA, Sheba HF, et al. Bone Mineral Density in Egyptian Children with Familial Mediterranean Fever. Iran J Med Sci. 2016;41(1):2–8.

52. Ben-Chetrit E, Berkun Y, Ben-Chetrit E, Ben-Chetrit A. The outcome of pregnancy in the wives of men with familial mediterranean fever treated with colchicine. Semin Arthritis Rheum. 2004;34(2):549–552. doi: 10.1016/j.semarthrit.2004.07.004.

53. Ben-Chetrit E, Ben-Chetrit A, Berkun Y, Ben-Chetrit E. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res (Hoboken). 2010;62(2):143–148. doi: 10.1002/acr.20061.

54. Marek-Yagel D, Berkun Y, Padeh S, et al. Clinical disease among patients heterozygous for familial Mediterranean fever. Arthritis Rheum. 2009;60(6):1862–1866. doi: 10.1002/art.24570.

55. Booty MG, Chae JJ, Masters SL, et al. Familial Mediterranean fever with a single MEFV mutation: where is the second hit? Arthritis Rheum. 2009;60(6):1851–1861. doi: 10.1002/art.24569.

56. Ter Haar N, Lachmann H, Ozen S, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis. 2013;72(5):678–685. doi: 10.1136/annrheumdis-2011-201268.

57. Erken E, Ozer HT, Bozkurt B, et al. Early suppression of familial Mediterranean fever attacks by single medium dose methyl-prednisolone infusion. Joint Bone Spine. 2008;75(3):370–372. doi: 10.1016/j.jbspin.2007.10.004.

58. Ozen S, Demirkaya E, Erer B, et al. EULAR recommendations for the management of familial Mediterranean fever. Ann Rheum Dis. 2016;75(4):644–651. doi: 10.1136/annrheumdis-2015-208690.

59. Goldfinger SE. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287(25):1302. doi: 10.1056/NEJM197212212872514.

60. Dinarello CA, Wolff SM, Goldfinger SE, et al. Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med. 1974;291(18):934–937. doi: 10.1056/NEJM197410312911804.

61. Kallinich T, Haffner D, Niehues T, et al. Colchicine use in children and adolescents with familial Mediterranean fever: literature review and consensus statement. Pediatrics. 2007;119:e474–483. doi: 10.1542/peds.2006-1434.

62. Ozturk MA, Kanbay M, Kasapoglu B, et al. Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol. 2011;29(4 Suppl 67):S77–86.

63. Manna R, Cerquaglia C, Curigliano V, et al. Clinical features of familial Mediterranean fever: an Italian overview. Eur Rev Med Pharmacol Sci. 2009;13 Suppl 1:51–53.

64. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum. 1998;28(1):48–59. doi: 10.1016/s0049-0172(98)80028-0.

65. Padeh S, Gerstein M, Berkun Y. Colchicine is a safe drug in children with Familial Mediterranean Fever. J Pediatr. 2012;161(6): 1142–1146. doi: 10.1016/j.jpeds.2012.05.047.

66. Berkun Y, Wason S, Brik R, et al. Pharmacokinetics of colchicine in pediatric and adult patients with familial Mediterranean fever. Int J Immunopathol Pharmacol. 2012;25(4):1121–1130. doi: 10.1177/039463201202500429.

67. Ozen S, Bilginer Y, Aktay Ayaz N, Calguneri M. Anti-interleukin 1 treatment for patients with familial Mediterranean fever resistant to colchicine. J Rheumatol. 2011;38(3):516–518. doi: 10.3899/jrheum.100718.

68. Meinzer U, Quartier P, Alexandra JF, et al. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum. 2011;41(2):265–271. doi: 10.1016/j.semarthrit.2010.11.003.

69. Sakallioglu O, Duzova A, Ozen S. Etanercept in the treatment of arthritis in a patient with familial Mediterranean fever. Clin Exp Rheumatol. 2006;24(4):435–437.

70. Hashkes P, Spalding SJ, Giannini EH, et al. Rilonacept for colchicines-resistant or –intolerant familial Mediterranean fever: a randomized trial. Ann Intern Med. 2012;157(8):533–541. doi: 10.7326/0003-4819-157-8-201210160-00003.

71. De Benedetti F, Anton J, Ben-Chetrit E, et al. Efficacy and safety of canakinumab in patients with periodic fever syndromes (colchicine-resistant FMF, HIDS/MKD and TRAPS): results from a Phase 3, Pivotal, Umbrella Trial. Arthritis Rheumatol. 2016;68 (Suppl 10):3205.

72. Akar S, Cetin P, Kalyoncu U, et al. Nationwide experience with off-label use of interleukin-1 targeting treatment in Familial Mediterranean Fever patients. Arthritis Care Res (Hoboken). 2018;70(7):1090–1094. doi: 10.1002/acr.23446.

73. Varan O, Kucuk H, Babaoglu H, et al. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol. 2018:1–4. doi: 10.1080/14397595.2018.1457469.

74. Laskari K, Boura P, Dalekos GN, et al. Longterm beneficial effect of canakinumab in colchicine-resistant Familial Mediterranean Fever. J Rheumatol. 2017;44(1):102–109. doi: 10.3899/jrheum.160518.


Для цитирования:


Костик М.М., Жогова О.В., Лагунова Н.В., Ивановский С.В., Колобова О.Л., Мельникова Л.Н. Семейная средиземноморская лихорадка: современные подходы к диагностике и лечению. Вопросы современной педиатрии. 2018;17(5):371-380. https://doi.org/10.15690/vsp.v17i5.1953

For citation:


Kostik M.M., Zhogova O.V., Lagunova N.V., Ivanovskiy S.V., Kolobova O.L., Melnikova L.N. Familial Mediterranean Fever: Current Approaches to Diagnosis and Treatment. Current pediatrics. 2018;17(5):371-380. (In Russ.) https://doi.org/10.15690/vsp.v17i5.1953

Просмотров: 179


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)